What are the latest clinical trials for Prostate Cancer in 2026

Latest Clinical Trials for Prostate Cancer in 2026

I appreciate your question about current clinical trials. Based on the educational resources available to me, I can share what leading prostate cancer experts are working on, though I should note that my most recent detailed information comes from 2023 presentations.

Key Treatment Directions Being Studied

According to Dr. [removed] Armstrong's presentation on Advanced Prostate Cancer, the field is actively pursuing several promising approaches:

1. PARP Inhibitor + Androgen Receptor (AR) Inhibitor Combinations

For patients with metastatic castration-resistant prostate cancer (especially those with BRCA mutations), researchers are combining:

• PARP inhibitors (like olaparib) with AR inhibitors (like abiraterone)
• These work by blocking DNA repair while also blocking testosterone signaling, overwhelming cancer cells with DNA damage
• Three drug approvals in this combination category have been achieved

2. T-Cell Bispecific Therapies

According to Dr. [removed] Subudhi's immunotherapy presentation, T-cell bispecifics are considered "the backbone of immunotherapy treatments" going forward. These therapies:

• Bring immune T-cells directly to cancer cells
• Target prostate-specific antigens like PSMA, STEAP, TROP2, and B7-H3
• Example: AMG-509 (a bispecific T-cell engager against STEAP-1) was being presented at ESMO

3. Radiopharmaceuticals (PSMA-Targeted)

• Pluvicto (177Lu-PSMA-617) continues to be refined
• The PSMA-Fore study was comparing Pluvicto with AR inhibitors in taxane-naïve patients
• About one-third of patients show strong responses, one-third show modest benefit, and one-third show limited response

4. Immunotherapy Combinations

Research is exploring:

• Checkpoint inhibitors (like pembrolizumab/Keytruda) combined with other therapies
• Bipolar Androgen Therapy (BAT) combined with immune checkpoint blockers (nivolumab showed 40% PSA response rate in the COMBAT trial)
• Radiation therapy combined with immunotherapy to boost immune system effectiveness

5. Neuroendocrine Prostate Cancer Research

This aggressive variant is receiving dedicated attention:

• Platinum-based chemotherapy combinations
• Immunotherapy approaches
• Novel cell surface receptor targeting (like bombesin receptors)
• The CHAMP study combines chemotherapy with two checkpoint inhibitors for aggressive variants

Important Testing Advances

Dr. [removed] Sartor emphasizes that patients should ask about:

• Genetic testing (DNA/RNA sequencing) to identify BRCA1/BRCA2 mutations and other actionable mutations
• Liquid biopsies (blood tests for circulating tumor DNA) to monitor disease response
• Microsatellite instability (MSI) testing to predict immunotherapy response
• Spatial/single-cell analysis to understand the tumor microenvironment

Questions to Ask Your Oncologist About 2026 Trials

1. "Are there clinical trials available for my specific stage and genetic profile?" (Ask about BRCA status, MSI, and other biomarkers)

2. "Which combination approaches are being studied for my situation—AR inhibitors with PARP inhibitors, immunotherapy combinations, or radiopharmaceuticals?"

3. "Have I had comprehensive genetic testing (both tumor and germline) to identify which targeted therapies might work best for me?"

4. "Are there trials combining radiation with immunotherapy that might be appropriate?"

5. "What biomarker tests would help predict which treatment I'm most likely to respond to?"

Important Context

According to the experts, treatment intensification is now standard of care—meaning combination approaches rather than single drugs are increasingly the norm. The field is moving toward:

• Earlier use of potent AR inhibitors
• Personalized medicine based on tumor genetics
• Better prediction of who will respond to which treatments
• Whole-patient care (managing side effects, cardiovascular health, quality of life)

Finding Current Trials

For the most up-to-date 2026 trial information, I recommend:

• ClinicalTrials.gov - Search for "prostate cancer" and filter by your location and disease stage
• NCCN Guidelines (National Comprehensive Cancer Network) - Updated regularly with latest trial recommendations
• Your oncologist - They have access to trials specific to your case and can discuss eligibility

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial participation.